Arjan Malekzadeh1, Cyra Leurs2, Wessel van Wieringen3, Martijn D Steenwijk4, Menno M Schoonheim4, Michael Amann5,6, Yvonne Naegelin7, Jens Kuhle7, Joep Killestein2, Charlotte E Teunissen1. 1. Department of Clinical Chemistry, Amsterdam University Medical Centre, Amsterdam, The Netherlands. 2. Department of Neurology, Amsterdam University Medical Centre, Amsterdam, The Netherlands. 3. Department of Mathematics, Amsterdam University Medical Centre, Amsterdam, The Netherlands. 4. Department of Anatomy and Neurosciences, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam University Medical Centre, Amsterdam, The Netherlands. 5. Division of Diagnostic and Interventional Neuroradiology, Department of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland. 6. Medical Image Analysis Center (MIAC AG), Basel, Switzerland. 7. Department of Biomedicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
Abstract
BACKGROUND: The pathophysiology of multiple sclerosis disease progression remains undetermined. The aim of this study was to identify differences in plasma proteome during different stages of MS disease progression. METHODS: We used a multiplex aptamer proteomics platform (Somalogic) for sensitive detection of 1129 proteins in plasma. MS patients were selected and categorized based on baseline and a 4-year follow-up EDSS (delta EDSS) scores; relapse-onset (RO) slow progression (n = 31), RO with rapid progression (n = 29), primary progressive (n = 30), and healthy controls (n = 20). The relation of baseline plasma protein levels with delta EDSS and different MRI progression parameters were assessed using linear regression models. RESULTS: Regression analyses of plasma proteins with delta EDSS showed six significant associations. Strong associations were found for the proteins LGLAS8 (P = 7.64 × 10-5 , q = 0.06), CCL3 (P = 0.0001, q = 0.06), and RGMA (P = 0.0005, q = 0.09). In addition, associations of plasma proteins were found with percentage brain volume for C3 (P = 2,08 × 10-9 , q = 1,70 × 10-6 ), FGF9 (P = 3,42 × 10-9 , q = 1,70 × 10-6 ), and EHMT2 (P = 0.0007, q = 0.01). Most of the significant markers were associated with cell-cell and cell-extracellular matrix adhesion, immune system communication, immune system activation, and complement pathways. CONCLUSIONS: Our results revealed eight novel biomarkers related to clinical and radiological progression in MS. These results indicate that changes in immune system, complement pathway and ECM remodeling proteins contribute to MS progression and may therefore be further explored for use in prognosis of MS.
BACKGROUND: The pathophysiology of multiple sclerosis disease progression remains undetermined. The aim of this study was to identify differences in plasma proteome during different stages of MS disease progression. METHODS: We used a multiplex aptamer proteomics platform (Somalogic) for sensitive detection of 1129 proteins in plasma. MS patients were selected and categorized based on baseline and a 4-year follow-up EDSS (delta EDSS) scores; relapse-onset (RO) slow progression (n = 31), RO with rapid progression (n = 29), primary progressive (n = 30), and healthy controls (n = 20). The relation of baseline plasma protein levels with delta EDSS and different MRI progression parameters were assessed using linear regression models. RESULTS: Regression analyses of plasma proteins with delta EDSS showed six significant associations. Strong associations were found for the proteins LGLAS8 (P = 7.64 × 10-5 , q = 0.06), CCL3 (P = 0.0001, q = 0.06), and RGMA (P = 0.0005, q = 0.09). In addition, associations of plasma proteins were found with percentage brain volume for C3 (P = 2,08 × 10-9 , q = 1,70 × 10-6 ), FGF9 (P = 3,42 × 10-9 , q = 1,70 × 10-6 ), and EHMT2 (P = 0.0007, q = 0.01). Most of the significant markers were associated with cell-cell and cell-extracellular matrix adhesion, immune system communication, immune system activation, and complement pathways. CONCLUSIONS: Our results revealed eight novel biomarkers related to clinical and radiological progression in MS. These results indicate that changes in immune system, complement pathway and ECM remodeling proteins contribute to MS progression and may therefore be further explored for use in prognosis of MS.
Authors: Andrea Nova; Teresa Fazia; Ashley Beecham; Valeria Saddi; Marialuisa Piras; Jacob L McCauley; Carlo Berzuini; Luisa Bernardinelli Journal: Life (Basel) Date: 2022-01-20
Authors: Ferdinanda Annesi; Sonia Hermoso-Durán; Bruno Rizzuti; Rosalinda Bruno; Domenico Pirritano; Alfredo Petrone; Francesco Del Giudice; Jorge Ojeda; Sonia Vega; Oscar Sanchez-Gracia; Adrian Velazquez-Campoy; Olga Abian; Rita Guzzi Journal: J Pers Med Date: 2021-04-13
Authors: Angelique Florentinus-Mefailoski; Peter Bowden; Philip Scheltens; Joep Killestein; Charlotte Teunissen; John G Marshall Journal: Clin Proteomics Date: 2021-06-28 Impact factor: 3.988
Authors: Ting Li; He Li; Yue Li; Shu-An Dong; Ming Yi; Qiu-Xia Zhang; Bin Feng; Li Yang; Fu-Dong Shi; Chun-Sheng Yang Journal: Front Genet Date: 2021-07-21 Impact factor: 4.599